Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

J Hematol Oncol · 2018 · PMC5975422 · PMID 29843755

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

marginally significantP = 0.09so close (0.05 < p ≤ 0.1)

The difference between arms A and C was marginally significant ( P = 0.09), but the difference between arms A and B was not significant ( P = 0.20; Fig. 3a ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.